2017
Integrated Tuberculosis/Human Immunodeficiency Virus Community-Based Case Finding in Rural South Africa: Implications for Tuberculosis Control Efforts
Shenoi SV, Moll AP, Brooks RP, Kyriakides T, Andrews L, Kompala T, Upadhya D, Altice FL, Eksteen FJ, Friedland G. Integrated Tuberculosis/Human Immunodeficiency Virus Community-Based Case Finding in Rural South Africa: Implications for Tuberculosis Control Efforts. Open Forum Infectious Diseases 2017, 4: ofx092. PMID: 28695145, PMCID: PMC5499582, DOI: 10.1093/ofid/ofx092.Peer-Reviewed Original ResearchHuman immunodeficiency virusIntensive case findingCase findingResistant TBTB casesHIV testingRural South AfricaOverall case notification rateConcurrent HIV testingHIV coinfection rateHIV-negative tuberculosisMedian CD4 countCD4 cell countHIV/TBDrug-resistant TBCase notification ratesCase-finding strategyHIV-positive individualsHigh-risk populationTB symptom screeningPopulation-level ratesCD4 countTuberculosis symptomsSymptom screeningTB elimination
2013
A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice
Bruce RD, Moody DE, Altice FL, Gourevitch MN, Friedland GH. A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice. Expert Review Of Clinical Pharmacology 2013, 6: 249-269. PMID: 23656339, PMCID: PMC4198941, DOI: 10.1586/ecp.13.18.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyAntiretroviral therapyDrug interactionsAgonist therapyHIV medicationsHepatitis C virus medicationsHepatitis C virus (HCV) treatmentActive antiretroviral therapyC virus treatmentPharmacodynamic drug interactionsImportant clinical consequencesReview of abstractsHCV therapyAntiretroviral agentsPharmacodynamic interactionsPharmacological interactionsHIV therapyClinical consequencesVirus treatmentClinical practiceFollowing keywordsTherapyClinical implicationsMedicationsMethadone
2012
Survival from XDR-TB Is Associated with Modifiable Clinical Characteristics in Rural South Africa
Shenoi SV, Brooks RP, Barbour R, Altice FL, Zelterman D, Moll AP, Master I, van der Merwe TL, Friedland GH. Survival from XDR-TB Is Associated with Modifiable Clinical Characteristics in Rural South Africa. PLOS ONE 2012, 7: e31786. PMID: 22412840, PMCID: PMC3295798, DOI: 10.1371/journal.pone.0031786.Peer-Reviewed Original ResearchConceptsXDR-TB patientsDrug-resistant tuberculosisRetrospective case-control studyXDR-TB casesCommunity-based hospitalCase-control studyGlobal public healthHIV coinfectionMicrobiological correlatesModifiable factorsAvailable interventionsRural South AfricaControl studyPatientsTuberculosisPublic healthSurvivorsSurvivalDaysHospitalMortalityChapter 40 HIV disease among substance users treatment issues
Bruce R, Altice F, Friedland G. Chapter 40 HIV disease among substance users treatment issues. 2012, 537-549. DOI: 10.1016/b978-1-4557-0695-2.00040-7.Peer-Reviewed Original Research
2011
Computer-Based Intervention in HIV Clinical Care Setting Improves Antiretroviral Adherence: The LifeWindows Project
Fisher JD, Amico KR, Fisher WA, Cornman DH, Shuper PA, Trayling C, Redding C, Barta W, Lemieux AF, Altice FL, Dieckhaus K, Friedland G, for the LifeWindows Team. Computer-Based Intervention in HIV Clinical Care Setting Improves Antiretroviral Adherence: The LifeWindows Project. AIDS And Behavior 2011, 15: 1635. PMID: 21452051, DOI: 10.1007/s10461-011-9926-x.Peer-Reviewed Original ResearchConceptsHIV clinical care settingsAdherence support interventionsClinical care sitesClinical care settingsHIV careCare visitsAntiretroviral adherenceControl armCare settingsCare sitesProtocol interventionTreat sampleProtocol sampleSupport interventionsComputer-based interventionsIntervention impactControl participantsInterventionAdherenceHIVPatientsCareHigh levelsClinicARV
2010
Pharmacokinetic Interactions Between Buprenorphine/Naloxone and Once-Daily Lopinavir/Ritonavir
Bruce RD, Altice FL, Moody DE, Morse GD, Andrews L, Lin SN, Fang WB, Ma Q, Friedland GH. Pharmacokinetic Interactions Between Buprenorphine/Naloxone and Once-Daily Lopinavir/Ritonavir. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2010, 54: 511-514. PMID: 20672450, PMCID: PMC4841260, DOI: 10.1097/qai.0b013e3181d3cad3.Peer-Reviewed Original ResearchConceptsLPV/rBuprenorphine/naloxoneHIV-seronegative subjectsLopinavir/ritonavirOpioid withdrawalPharmacokinetic interactionsDaily lopinavir/ritonavirDaily LPV/rSteady-state pharmacokinetic evaluationBuprenorphine pharmacokineticsR administrationDosage modificationNaloxone concentrationsHistorical controlsPharmacodynamic responseAUC0-24hBaseline valuesPharmacokinetic evaluationNaloxonePharmacokinetic studySignificant differencesRitonavirNLXCmaxClearanceTreatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs
Altice FL, Kamarulzaman A, Soriano VV, Schechter M, Friedland GH. Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. The Lancet 2010, 376: 367-387. PMID: 20650518, PMCID: PMC4855280, DOI: 10.1016/s0140-6736(10)60829-x.Peer-Reviewed Original ResearchMeSH KeywordsAIDS-Related Opportunistic InfectionsAnti-HIV AgentsAntipsychotic AgentsAntitubercular AgentsAntiviral AgentsBacterial InfectionsComorbidityCriminal LawDrug InteractionsDrug Resistance, BacterialEvidence-Based MedicineHepatitis, Viral, HumanHIV InfectionsHumansMedication AdherenceMental DisordersNarcoticsPrisonersSubstance-Related DisordersTuberculosisConceptsSubstance use disordersDrug usersAntiretroviral therapyViral hepatitisHIV treatmentHealth of HIVPharmacokinetic drug interactionsSubstance use comorbiditiesMedication-assisted therapyEvidence-based treatmentsDrug-resistant strainsHealth-related outcomesHealth service deliveryInfectious complicationsMultiple comorbiditiesHIV infectionPsychiatric comorbidityPoor adherenceClinical managementCardiovascular diseaseInadequate prescriptionCongregate settingsDrug interactionsComorbiditiesHIVPreparing for highly active antiretroviral therapy rollout in rural South Africa: an assessment using the information, motivation, and behavioral skills model
Simon MD, Altice FL, Moll AP, Shange M, Friedland GH. Preparing for highly active antiretroviral therapy rollout in rural South Africa: an assessment using the information, motivation, and behavioral skills model. AIDS Care 2010, 22: 462-474. PMID: 20204909, DOI: 10.1080/09540120903220253.Peer-Reviewed Original ResearchConceptsActive antiretroviral therapy rolloutAntiretroviral therapy rolloutHIV/AIDSHAART rolloutHAART outcomesFolk remediesHIV treatment optimismMedication-taking behaviorOverall correct scoreBetter treatment outcomesResource-limited settingsBehavioral skills modelCommunity-based assessmentHAART initiationHIV optimismHIV testingHIV serostatusTreatment optimismTreatment outcomesSide effectsRural South AfricaCondom useHAARTTugela FerryYoung adults
2009
Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone
Bruce RD, Altice FL, Moody DE, Lin SN, Fang WB, Sabo JP, Wruck JM, Piliero PJ, Conner C, Andrews L, Friedland GH. Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone. Drug And Alcohol Dependence 2009, 105: 234-239. PMID: 19726139, PMCID: PMC2779257, DOI: 10.1016/j.drugalcdep.2009.07.007.Peer-Reviewed Original ResearchConceptsTPV/rBuprenorphine/naloxonePharmacokinetic interactionsBuprenorphine/naloxone therapySteady-state pharmacokinetic evaluationOpioid replacement therapyHIV-negative subjectsHIV-seronegative subjectsOpioid withdrawal symptomsHistorical control subjectsTipranavir/ritonavirConcentration-time profilesRTV levelsAntiretroviral medicationsDosage modificationNaloxone therapyTreatment medicationsOpioid dependenceReplacement therapyWithdrawal symptomsControl subjectsPharmacokinetic effectsHIV therapyPharmacokinetic evaluationNLX
2008
Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone
Bruce R, Altice F, Moody D, Lin S, Fang W, Sabo J, Wruck J, Conner C, Piliero P, Andrews L, Friedland G. Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone. Journal Of The International AIDS Society 2008, 11: p240. DOI: 10.1186/1758-2652-11-s1-p240.Peer-Reviewed Original ResearchPharmacokinetic drug interactions between drugs of abuse and antiretroviral medications: implications and management for clinical practice
Bruce RD, Altice FL, Friedland GH. Pharmacokinetic drug interactions between drugs of abuse and antiretroviral medications: implications and management for clinical practice. Expert Review Of Clinical Pharmacology 2008, 1: 115-127. PMID: 24410515, DOI: 10.1586/17512433.1.1.115.Peer-Reviewed Original ResearchPharmacokinetic drug interactionsDrugs of abuseDrug interactionsAntiretroviral therapyHIV treatmentActive illicit drug useClinical implicationsImportant pharmacokinetic drug interactionsClinical case seriesImportant clinical consequencesIllicit drug useHIV/AIDSMetabolism of drugsPharmacokinetic interaction studyAntiretroviral medicationsCase seriesTreatable diseaseClinical consequencesClinical practiceDrug useMedical consequencesSubstance abuseTherapyDrugsAbuseCHAPTER 44 HIV Disease Among Substance Users: Treatment Issues
Bruce R, Altice F, Friedland G. CHAPTER 44 HIV Disease Among Substance Users: Treatment Issues. 2008, 513-526. DOI: 10.1016/b978-1-4160-2882-6.50048-4.Chapters
2007
Superiority of Directly Administered Antiretroviral Therapy over Self-Administered Therapy among HIV-Infected Drug Users: A Prospective, Randomized, Controlled Trial
Altice FL, Maru DS, Bruce RD, Springer SA, Friedland GH. Superiority of Directly Administered Antiretroviral Therapy over Self-Administered Therapy among HIV-Infected Drug Users: A Prospective, Randomized, Controlled Trial. Clinical Infectious Diseases 2007, 45: 770-778. PMID: 17712763, PMCID: PMC2693907, DOI: 10.1086/521166.Peer-Reviewed Original ResearchConceptsHIV-1 RNA levelsSelf-administered therapyT-lymphocyte countsDrug usersAntiretroviral therapyLymphocyte countRNA levelsPrimary outcomeProportion of patientsGreater mean reductionHIV treatment programsLog10 copies/Human immunodeficiency virusCopies/mLDAART groupVirologic outcomesSecondary outcomesControlled TrialsImmunodeficiency virusPoor adherenceTreatment adherenceEntry criteriaTreat approachCopies/Mean changeAntiretroviral Treatment Regimen Outcomes Among HIV-Infected Prisoners
Springer SA, Friedland GH, Doros G, Pesanti E, Altice FL. Antiretroviral Treatment Regimen Outcomes Among HIV-Infected Prisoners. HIV Research & Clinical Practice 2007, 8: 205-212. PMID: 17720660, PMCID: PMC2409059, DOI: 10.1310/hct0804-205.Peer-Reviewed Original ResearchConceptsAntiretroviral therapyImmunological outcomesHIV-1 RNA levelsCells/mulActive antiretroviral therapyEffective antiretroviral therapyRetrospective cohort studyDuration of therapyKaplan-Meier curvesHIV-1 RNAProportion of subjectsHAART strategyTriple NRTICohort studyCopies/Incarceration periodsTreatment strategiesHigh prevalenceMean changeStudy groupNRTIsHIVTherapyRNA levelsLaboratory data
2006
Pharmacokinetic Drug Interactions Between Opioid Agonist Therapy and Antiretroviral Medications
Bruce RD, Altice FL, Gourevitch MN, Friedland GH. Pharmacokinetic Drug Interactions Between Opioid Agonist Therapy and Antiretroviral Medications. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2006, 41: 563-572. PMID: 16652030, DOI: 10.1097/01.qai.0000219769.89679.ec.Peer-Reviewed Original ResearchConceptsPharmacokinetic drug interactionsOpioid agonist therapyDrug interactionsAgonist therapyAntiretroviral therapyAntiretroviral medicationsImportant pharmacokinetic drug interactionsClinical case seriesImportant clinical consequencesClass of agentsHIV/AIDSPharmacokinetic interaction studyAntiretroviral agentsCase seriesOpioid dependenceHIV treatmentTreatable diseaseHIV therapyClinical consequencesFollowing keywordsMethadoneTherapyClinical implicationsLanguage articlesMedications
2004
Developing a Directly Administered Antiretroviral Therapy Intervention for HIV-Infected Drug Users: Implications for Program Replication
Altice FL, Mezger JA, Hodges J, Bruce RD, Marinovich A, Walton M, Springer SA, Friedland GH. Developing a Directly Administered Antiretroviral Therapy Intervention for HIV-Infected Drug Users: Implications for Program Replication. Clinical Infectious Diseases 2004, 38: s376-s387. PMID: 15156426, DOI: 10.1086/421400.Peer-Reviewed Original ResearchConceptsMedian HIV-1 RNA loadDrug usersHIV-1 RNA loadMost subjectsHuman immunodeficiency virusSelf-administered therapySyringe exchange programsMedian CD4Antiretroviral therapyDaily regimensMedical comorbiditiesImmunodeficiency virusEmergency departmentRNA loadMethadone clinicsMedication administrationOwn medicationsCopies/Major depressionMedical appointmentsTherapy interventionCell countDAARTCells/Medical services
2003
Pilot study to enhance HIV care using needle exchange-based health services for out-of-treatment injecting drug users
Altice FL, Springer S, Buitrago M, Hunt DP, Friedland GH. Pilot study to enhance HIV care using needle exchange-based health services for out-of-treatment injecting drug users. Journal Of Urban Health 2003, 80: 416-427. PMID: 12930880, PMCID: PMC3455979, DOI: 10.1093/jurban/jtg053.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusNondetectable viral loadCD4 lymphocyte countDrug treatmentDrug usersLymphocyte countViral loadHIV therapyBaseline HIV-1 RNA levelsNeedle exchangeHealth servicesHIV-1 RNA levelsPilot studyPotent antiretroviral combinationUtilization of HAARTActive antiretroviral therapyAntiretroviral therapy regimensHIV-1 RNACommunity-based health interventionsAdverse side effectsActive drug usersFormal drug treatmentImmunodeficiency syndrome (AIDS) incidenceSmall pilot studyActive heroin injectors
2002
Increasing drug users’ adherence to HIV treatment: results of a peer-driven intervention feasibility study
Broadhead RS, Heckathorn DD, Altice FL, van Hulst Y, Carbone M, Friedland GH, O’Connor P, Selwyn PA. Increasing drug users’ adherence to HIV treatment: results of a peer-driven intervention feasibility study. Social Science & Medicine 2002, 55: 235-246. PMID: 12144138, DOI: 10.1016/s0277-9536(01)00167-8.Peer-Reviewed Original ResearchConceptsActive drug usersDrug users' adherenceDrug usersDrug treatmentMedical carePrimary careIntervention feasibility studySocial support structuresHealth advocatesUser adherenceTreatment program staffPeer-driven interventionHIV diseaseHIV infectionPatient adherenceSix-month studyHIV treatmentPhysician referralClinical appointmentsHIV therapeuticsCarePositive behavioral changesAdherencePeer pressureTreatment
2001
Trust and the Acceptance of and Adherence to Antiretroviral Therapy.
Altice FL, Mostashari F, Friedland GH. Trust and the Acceptance of and Adherence to Antiretroviral Therapy. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2001, 28: 47. PMID: 11579277, DOI: 10.1097/00042560-200109010-00008.Peer-Reviewed Original ResearchConceptsInjection drug usersAntiretroviral therapyPotent new therapyStandardized chart reviewSocial isolationDrugs of abuseAntiretroviral regimenHIV clinicChart reviewHIV infectionHIV medicationsObserved therapyCorrelates of acceptanceHealth beliefsClinical informationHealth locusNew therapiesSide effectsPharmacy reviewDrug usersHealth statusInfected prisonersAIDS incidenceTherapyTherapeutic agentsTrust and the Acceptance of and Adherence to Antiretroviral Therapy
Altice F, Mostashari F, Friedland G. Trust and the Acceptance of and Adherence to Antiretroviral Therapy. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2001, 28: 47-58. DOI: 10.1097/00126334-200109010-00008.Peer-Reviewed Original ResearchInjection drug usersAntiretroviral therapyPotent new therapyStandardized chart reviewSocial isolationDrugs of abuseAntiretroviral regimenHIV clinicChart reviewHIV infectionHIV medicationsObserved therapyCorrelates of acceptanceHealth beliefsClinical informationHealth locusNew therapiesSide effectsPharmacy reviewDrug usersHealth statusInfected prisonersAIDS incidenceTherapyTherapeutic agents